Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia
Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular Tachycardia
The purpose of this study is to determine whether intravenous amiodarone has less cardiac
 significant adverse events compared to intravenous procainamide in the acute treatment of
 haemodynamically well tolerated wide QRS tachycardia, the majority of them of probably
 ventricular origen.
Multicenter, prospective and randomized study in phase IV. A total of 302 patients will be
 included in the study within 40-50 institutions in Spain. Patients with regular and
 monomorphic tachycardia ≥ 120 bpm, QRS ≥ 120 ms and haemodynamically well tolerated will be
 randomized to receive iv amiodarone (single dosage: 5 mg/kg in 20 minutes) vs iv procainamide
 (single dosage: 10 mg/kg in 20 minutes). The study period will be 40 minutes from infusion
 initiation. Study variables include the presence of clinically cardiac significant adverse
 events: hypotension, syncope, heart failure, symptomatic sinus bradycardia, AV block,
 proarrhythmia and tachycardia acceleration (<20 lpm)and death. Total observation period will
 be 24 hours after the end of the infusion.
Inclusion Criteria:

 -  Patients with stable tachycardia ≥120 lpm, QRS ≥120 ms and haemodynamically well
 tolerated defined as: 1)Systolic blood pressure ≥90 mmHg, 2) absence of dyspnea at
 rest, 3)absence of peripheric hypoperfusion signs and 4)no severe angina.

 -  Age > 18 years

 -  Written inform consent obtained

 Exclusion Criteria:

 -  Treatment with iv amiodarone or iv procainamide during the previous 24 hours

 -  QRS tachycardia <120 ms

 -  Patients with QRS ≥120 ms tachycardia with haemodynamic compromise that requires
 urgent cardioversion for termination

 -  Irregular tachycardia

 -  Tachycardia that is considered as supraventricular due to physician criteria
 (adenosine and/or vagal manoeuvres response)

 -  Patient that do not want to cooperate